Roche’s new influenza drug Xofluza can dramatically prevent the spread of the virus when used as a preventive therapy, according to new phase 3 data. Xofluza (baloxavir marboxil) is already ...

The FDA has approved a new use for Xofluza (baloxavir marboxil) from Roche’s Genentech unit, to prevent people developing flu after coming into contact with an infectious person.

“This could be a breakthrough in the way that we treat influenza.” Data from the drugmaker, Shionogi, show that while Xofluza works days faster than Tamiflu in stopping the flu virus, symptoms wrap up ...

This rush has led to shortages and price hikes, with some pharmacies selling the drug for up to 300 yuan (£33) per box. Xofluza, which contains the active ingredient baloxavir marboxil ...

Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug. Kerry served as The Scientist’s news ...

Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of influenza virus, from an infected person to household members by 32% – – ...

The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%.